Attached files

file filename
EX-99.2 - PHARMACYCLICS INCex992to8k07380_06062011.htm
EX-99.1 - PHARMACYCLICS INCex991to8k07380_06062011.htm
EX-99.3 - PHARMACYCLICS INCex993to8k07380_06062011.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 6, 2011
 
PHARMACYCLICS, INC.
(Exact name of registrant as specified in its charter)
     
Delaware
000-26658
94-3148201
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
     
995 E. Arques Avenue, Sunnyvale, California
4085-4521
(Address of principal executive offices)
(Zip Code)

Registrant’s telephone number, including area code: (408) 774-0330

 
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 
 
Item 7.01.
Regulation FD Disclosure.
 
 
On June 6, 2011, Pharmacyclics, Inc., a Delaware corporation (the “Company”), announced results from the Phase IB/II study of the Btk inhibitor, PCI-32765, in chronic lymphocytic leukemia / small cell lymphocytic lymphoma (CLL/SLL), which results were presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting on June 6, 2011 (the “ASCO Meeting”). The foregoing description is qualified in its entirety by reference to the Company’s Press Release dated June 6, 2011 and the ASCO Presentation, copies of which are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are incorporated herein by reference. Additionally, as described in the Press Release, the Company is holding a conference call with investors on Monday, June 6, 2011 at 4:30 p.m. Eastern Time, to discuss the results presented at the ASCO Meeting and a general clinical update. Slides referenced during the conference call are attached hereto as Exhibit 99.3, which are incorporated herein by reference.
 
Item 9.01
Financial Statements and Exhibits.
 
 
(d)
Exhibits.
 
 
Exhibit No.
Description
 
 
99.1
Press Release of Pharmacyclics, Inc. dated June 6, 2011.
 
 
99.2
ASCO Presentation.
 
 
99.3
Investor Presentation.
 
 
 

 
 
SIGNATURE
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
June 6, 2011
 
PHARMACYCLICS, INC.
 
 
By:
/s/ Rainer M. Erdtmann
 
Name: Rainer M. Erdtmann
 
Title: Vice President, Finance & Administration and Secretary


 
 
3